Stella Pharma Corporation (4888.T)
JPY 555.0
(0.18%)
JPY 555.0
(0.18%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.44 Billion JPY | -8.43% |
| 2022 | 1.57 Billion JPY | -3.81% |
| 2021 | 1.63 Billion JPY | -9.83% |
| 2020 | 1.81 Billion JPY | -7.72% |
| 2019 | 1.96 Billion JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 2.17 Billion JPY | 50.77% |
| 2023 Q3 | 1.25 Billion JPY | -3.93% |
| 2023 FY | 1.44 Billion JPY | -8.43% |
| 2023 Q2 | 1.3 Billion JPY | -3.22% |
| 2023 Q1 | 1.35 Billion JPY | -14.35% |
| 2023 Q4 | 1.44 Billion JPY | 14.98% |
| 2022 Q2 | 1.62 Billion JPY | 0.0% |
| 2022 Q3 | 1.44 Billion JPY | -10.95% |
| 2022 Q4 | 1.57 Billion JPY | 9.23% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 55.539% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -2176.592% |
| GNI Group Ltd. | 26.34 Billion JPY | 94.52% |
| Linical Co., Ltd. | 10.3 Billion JPY | 85.991% |
| Trans Genic Inc. | 3.81 Billion JPY | 62.135% |
| MEDINET Co., Ltd. | 590.2 Million JPY | -144.595% |
| Soiken Holdings Inc. | 697.02 Million JPY | -107.111% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 52.21% |
| AnGes, Inc. | 2.78 Billion JPY | 48.246% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | -181.073% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 98.403% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | -308.641% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | 12.503% |
| Carna Biosciences, Inc. | 472.35 Million JPY | -205.62% |
| CanBas Co., Ltd. | 91.98 Million JPY | -1469.346% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | -32.005% |
| RaQualia Pharma Inc. | 809.83 Million JPY | -78.261% |
| Chiome Bioscience Inc. | 593.73 Million JPY | -143.142% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 66.065% |
| PeptiDream Inc. | 29.11 Billion JPY | 95.042% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | -154.83% |
| Ribomic Inc. | 155.8 Million JPY | -826.525% |
| SanBio Company Limited | 2.25 Billion JPY | 35.979% |
| Healios K.K. | 11.28 Billion JPY | 87.209% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -474.528% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | -291.222% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -497.776% |
| StemRIM | 187 Million JPY | -671.984% |
| CellSource Co., Ltd. | 677.73 Million JPY | -113.004% |
| FunPep Company Limited | 189.32 Million JPY | -662.508% |
| Kringle Pharma, Inc. | 596.95 Million JPY | -141.829% |
| TMS Co., Ltd. | 97.68 Million JPY | -1377.761% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -1477.819% |
| Cuorips Inc. | 200.96 Million JPY | -618.353% |
| K Pharma,Inc. | 209.13 Million JPY | -590.28% |
| Takara Bio Inc. | 11.42 Billion JPY | 87.359% |
| ReproCELL Incorporated | 741.03 Million JPY | -94.811% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | -57.305% |
| StemCell Institute Inc. | 3.85 Billion JPY | 62.508% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | -58.912% |
| CellSeed Inc. | 301.04 Million JPY | -379.53% |